A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) (NCT05489705)
Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study
🩺 Plain-English Summary (8th-Grade Level)
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting. Europe Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.
Who can join: Review the eligibility criteria below.
Location: Alaska Heart Institute — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (101 Sites)
Showing the first 25 of 101 sites.
- Alaska Heart Institute — Anchorage, Alaska
- Pima Heart and Vascular — Tucson, Arizona
- UAMS — Little Rock, Arkansas
- Local Institution - 0037 — La Jolla, California
- Keck School of Medicine of USC-Usc — Los Angeles, California
- Stanford Health Care Hospital & Clinics — Palo Alto, California
- University Of California San Francisco Medical Center — San Francisco, California
- UC Denver, AMC — Aurora, Colorado
- Local Institution - 0067 — Hartford, Connecticut
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Local Institution - 0065 — Jacksonville, Florida
- Local Institution - 0046 — Honolulu, Hawaii
- University of Chicago Dept of Medicine — Chicago, Illinois
- Indiana. University — Indianapolis, Indiana
- Franciscan Physician Network-Indiana Heart Physicians — Indianapolis, Indiana
- Local Institution - 0045 — Iowa City, Iowa
- Local Institution - 0059 — Baltimore, Maryland
- MedStar Health Research Institute — Baltimore, Maryland
- Harvard (Massachusetts General Hospital) — Boston, Massachusetts
- Harvard Medical School - Brigham and Women's Hospital (BWH) — Boston, Massachusetts
- Spectrum Health Medical Group — Grand Rapids, Michigan
- Henry Ford Health System — West Bloomfield, Michigan
- Minneapolis Heart Institute Foundation — Minneapolis, Minnesota
- Cardiology Associates Research, Llc — Tupelo, Mississippi
- St. Luke's Mid-America Heart Institute — Kansas City, Missouri
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obstructive Hypertrophic Cardiomyopathy
- Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM — Charlottesville, Virginia
- Real-world Patient Reported Outcomes Among Patients Treated With Camzyos — Boston, Massachusetts
Explore by condition: All Obstructive Hypertrophic Cardiomyopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.